Rigel Pharmaceuticals (RIGL) Operating Expenses (2010 - 2026)

Rigel Pharmaceuticals' Operating Expenses history runs 17 years deep, the most recent figure standing at $46.9 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 15.71% year-over-year to $46.9 million; the TTM figure through Mar 2026 stood at $175.2 million (up 10.08% YoY), while the FY2025 annual figure was $168.8 million, up 8.85% from the prior year.
• Operating Expenses for Q1 2026 stood at $46.9 million, up from $46.6 million in the prior quarter.
• The five-year high for Operating Expenses was $49.2 million in Q4 2022, with the low at $32.2 million in Q2 2023.
• The 5-year median for Operating Expenses is $40.8 million (2022), against an average of $40.2 million.
• The sharpest annual moves came in 2023 and 2024: Operating Expenses plunged 31.25% in 2023, then climbed 26.54% in 2024.
• Rigel Pharmaceuticals' Operating Expenses stood at $49.2 million in 2022, then slumped by 31.25% to $33.8 million in 2023, then gained by 21.03% to $40.9 million in 2024, then rose by 13.9% to $46.6 million in 2025, then rose by 0.65% to $46.9 million in 2026.
• Business Quant data shows RIGL's Operating Expenses at $46.9 million in Q1 2026, $46.6 million in Q4 2025, and $41.0 million in Q3 2025.